Home › NDC Lookup › RxCUI directory › RxCUI 1716099

Betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Foam [Enstilar] — RxCUI 1716099

RxNorm drug concept · Semantic branded drug
RxCUI 1716099 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1716099
Official nameBetamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Foam [Enstilar]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asEnstilar 0.005 % / 0.064 % Topical Foam; Enstilar (calcipotriene 0.005 % / betamethasone dipropionate 0.064 % ) Topical Foam
FDA products mapped1
Package NDCs mapped3
Reported Medicaid activity (SDUD)1,063 prescriptions · 10 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Calcipotriene Topical: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Calcipotriene is not a steroid at all — it's a synthetic form of vitamin D3. While steroid creams work by suppressing inflammation, calcipotriene is thought to work by binding to v...
  • What exactly is calcipotriene, and how is it different from a steroid cream?
  • No — calcipotriene should not be applied to the face. The label is clear on this for all product forms. If you have psoriasis on your face, talk to your dermatologist about other o...
  • Can I use this on my face if my psoriasis is there too?
📖 Read our full Calcipotriene Topical guide →

🕸️ Concept Web — How Betamethasone dipropionate 0.643 MG/ML / calcipo... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Foam [Enstilar] RxCUI 1716099

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 4

    The active substance itself — no strength, form, or brand attached yet.

    • Betamethasone 1514
    • Calcipotriene 29365
    • Betamethasone / calcipotriene 690419
    • Betamethasone dipropionate 19254
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Enstilar 1716095
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Betamethasone / calcipotriene Topical Foam 1716093
    • Betamethasone dipropionate / calcipotriene Topical Foam 2648710
    • Betamethasone / calcipotriene Topical Product 1153789
    • Betamethasone dipropionate / calcipotriene Topical Product 2660029
    • Betamethasone / calcipotriene Topical Foam [Enstilar] 1716097
    • Betamethasone dipropionate / calcipotriene Topical Foam [Enstilar] 2655324
    • Enstilar Topical Product 1716098
    • Topical Foam 346285
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 17 of 18 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Foam SCD · 1716094
  • Betamethasone dipropionate 0.643 MG/ML SCDC · 1716092
  • Calcipotriene 0.05 MG/ML SCDC · 340092
  • Betamethasone / calcipotriene Topical Foam SCDF · 1716093
  • Betamethasone dipropionate / calcipotriene Topical Foam SCDFP · 2648710
  • Betamethasone / calcipotriene Topical Product SCDG · 1153789
  • Betamethasone dipropionate / calcipotriene Topical Product SCDGP · 2660029

Brand-Name Concepts

  • Betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML [Enstilar] SBDC · 1716096
  • Betamethasone / calcipotriene Topical Foam [Enstilar] SBDF · 1716097
  • Betamethasone dipropionate / calcipotriene Topical Foam [Enstilar] SBDFP · 2655324
  • Enstilar Topical Product SBDG · 1716098
  • Enstilar BN · 1716095

📦 FDA Products & Package NDCs

1 product · 3 package NDCs
3 package NDCs map to RxCUI 1716099 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50222-0302-60 1 CAN in 1 CARTON (50222-302-60) / 60 g in 1 CAN ENSTILAR LEO Pharma Inc. 2015-10-16
50222-0302-66 2 CAN in 1 CARTON (50222-302-66) / 60 g in 1 CAN ENSTILAR LEO Pharma Inc. 2015-10-16
50222-0302-91 1 CAN in 1 CARTON (50222-302-91) / 60 g in 1 CAN ENSTILAR LEO Pharma Inc. 2015-10-16
Observed labelers: LEO Pharma Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per gm · median
$21.8342
Range $21.8342–$21.8342 · middle 50% $21.8342–$21.8342 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.